Women and human immunodeficiency virus: Unique management issues

American Journal of the Medical Sciences

Volumn 328, Issue 1, 2004, Pages 17-25

  Clark, Rebecca A ^a,b   Dumestre, Jeanne ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b HOP   (United States)

Author keywords

Cervical dysplasia; Contraception; HIV infected women; Pelvic inflammatory disease; Pregnancy

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

CHILD CARE; CONTRACEPTION; FEMALE; GYNECOLOGIC DISEASE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PERINATAL INFECTION; PRACTICE GUIDELINE; PREGNANCY; PRIMARY MEDICAL CARE; REVIEW; SEX DIFFERENCE; UNITED STATES; UTERINE CERVIX DYSPLASIA; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 3242688031     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200407000-00004     Document Type: Article

References (62)

1. AIDS Epidemic Update 2002. Available at http://www.unaids. org
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2001;13(No. 2):1-44. Available at http://www.cdc.gov/hiv/stats/hasrlink.HTM.
3. Stafford MK, Ward H, Flanagan A, et al. Safety study of nonoxynol 9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:327-31.
4. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338: 1281-2.
5. Department of Health and Human Services Antiretroviral Treatment Adult and Adolescent Guidelines. Available at http://aidsinfo.nih.gov/guidelines/.
6. Tackett D, Child M, Ararwala S, et al. Atazanavir: A summary of two pharmacokinetic drug interaction studies in healthy subjects (Abstract 543). 10th Conference on Retroviruses and Opportunistic Infections Boston, February 10-14, 2003.
7. Watts DH. Drug therapy: management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002; 346:1879-91.
8. Task Force on Postovulatory Methods of Fertility Regulations. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998;352:428-30.
9. American College of Obstetricians and Gynecologist Technical Bulletin. Preconceptional Care. Number 205, May 1995.
10. Department of Health and Human Services Maternal-Child Transmission Guidelines. Available at http://aidsinfo.nih. gov.guidelines/.
11. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94.
12. HIV-infected pregnant women and vertical transmission in Europe since 1986; European Collaborative Study. AIDS 2001;15:761-70.
13. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads less than 1,000 copies/ml. J Infect Dis 2001;183:539-45.
14. Dunn DT, Newell ML, Ades AE, et al. Risk of human immunodeficiency virus type 1 transmission through breast-feeding. Lancet 1992;340:585-8.
15. Coll O, Hernandez M, Boucher CA, et al. Vertical HIV-1 transmission correlates with high maternal viral load at delivery. J Acquir Immune Def Syndr Hum Retrovirol 1997; 4:26-30.
16. Pitt J, Brambilla D, Reichelderfer P, et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175:567-75.
17. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 346:1863-70.
18. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr Hum Retrovirol 2000;25:261-8.
19. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177: 557-64.
20. Conner EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-80.
21. Important drug warning: retyped text of a letter from Bristol-Myers Squibb: January 5, 2001. Rockville, MD: Food and Drug Administration, 2001. Available at http://www.fda.gov/medwatch/safety/2001/zerit&:videxletter.htm. Accessed May 21, 2002.
22. Ibdah JA, Yang Z, Bennett MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 200; 71:182-9.
23. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9.
24. Updated Package Insert for Efavirenz (Sustiva), April 2003. Available at http://www.sustiva.com.
25. The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in the prevention of vertical HIV-1 transmission: a randomized clinical trail. Lancet 1999;353:1035-9.
26. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15:357-68.
27. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Committee opinion. No. 234. Washington, D.C.: American College of Obstetricians and Gynecologists, May 2000.
28. Marcolet A, Goffinet F, Firtion G, et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002;186:784-9.
29. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1999;48:(RR-10):1-66. (2001 update available at http://www.hivatis.org).
30. Al-Khan A, Colon J, Palta V, et al. Assisted reproductive technology for men and women infected with human immunodeficiency virus type 1. Clin Infect Dis 2003;36:195-200.
31. Hamed KA, Winters MA, Holodiny M, et al. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis 1993;167: 798-802.
32. Ellerbrock TV, Wright TC, Bush T, et al. Characteristics of menstruation in women infected with human immunodeficiency virus. Obstet Gynecol 1996;87:1030-4.
33. Shah PN, Smith JR, Wells C, et al. Menstrual symptoms in women infected by the human immunodeficiency virus. Obstet Gynecol 1994;83:397-400.
34. Chirgwin KD, Feldman J, Muneyyirci-Delale O, et al. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1996;12:489-94.
35. Greenblat RM, Ameli N, Grant RM, et al. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis 2000;181:82-90.
36. Clark RA, Mulligan K, Stamenovic E, et al. Frequency of anovulation and early menopause among women enrolled in selected AIDS clinical trials group studies. J Infect Dis 2001; 184:1325-7.
37. Clark RA, Cohn S, Jarek C, et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr 2000;23:99-100.
38. Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines 2002. MMWR Morbid Mortal Wkly Rep 2002;51:1-80.
39. Cu-Uvin S, Hogan JW, Warren D, et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. Clin Infect Dis 1999;29:1145-50.
40. Warren D, Klein RS, Sobel J, et al. A multicenter study of bacterial vaginosis in women with or at risk for human immunodeficiency virus infection. Infect Dis Obstet Gynecol 2001;9:133-41.
41. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001;98:656-63.
42. Shifrin E, Matityahyu D, Feldman J, et al. Determinants of incident vulvovaginal candidiasis in human immunodeficiency virus-positive women. Infect Dis Obstet Gynecol 2000; 8:176-80.
43. Rhoads JL, Wright DC, Redfield RR, et al. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 1987;257:3105-7.
44. Sobel JD. Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. Int J STD AIDS 2002;13:358-62.
45. Greenblatt RM, Bacchetti P, Barkan S, et al. Lower genital tract infections among HIV-infected and high-risk uninfected women. Sex Trans Dis 1999;26:143-51.
46. Capps L, Peng G, Doyle M, et al. Sexually transmitted infections in women infected with the human immunodeficiency virus. Sex Trans Dis 1998;25:443-7.
47. Clark RA, Brandon W, Dumestre J, et al. Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. Clin Infect Dis 1993;17:173-7.
48. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000;27:284-8.
49. Hoegsberg B, Abulafia O, Sedlis A, et al. Sexually transmitted diseases and human immunodeficiency virus infection among women with pelvic inflammatory disease. Am J Obstet Gynecol 1990;163:1135-9.
50. Korn AP, Landers DV, Green JR, et al. Pelvic inflammatory disease in human immunodeficiency virus-infected women. Obstet Gynecol 1993;82:765-8.
51. Barbosa C, Macasaet M, Brockmann S, et al. Pelvic inflammatory disease and human immunodeficiency virus infection. Obstet Gynecol 1997;89:65-70.
52. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus inflection on pelvic inflammatory disease. Obstet Gynecol 2000;95:525-34.
53. Kamenga MC, De Cock KM, St. Louis ME, et al. The impact of human immunodeficiency virus infection on pelvic inflammatory disease: a case-control study in Abidjan, Ivory Coast. Am J Obstet Gynecol 1995;172:919-25.
54. Cohen CR, Sinei S, Reilly M, et al. Effect of human immunodeficiency virus 1 infection upon acute salpingitis in a laparoscopic study. J Infect Dis 1998;178:1352-8.
55. Bukesi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol 1999;18:1374-81.
56. Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002;15:519-22.
57. Anderson J, Clark RA, Watts H, et al. Idiopathic genital ulcers in women infected with human immunodeficiency virus: J Acquir Immune Defic Syndr 1996;13:343-7.
58. Verberkmoes A, Boer K, Wertheim PM, et al. Thalidomide for genital ulcer in HIV-positive women. Lancet 1996; 347:974.
59. Hellinger FJ. The use of health services by women with HIV infection. Health Serv Res 1993;28:543-61.
60. Stein MD, Liebman B, Waachtel TJ, et al. HIV-positive women: reasons they are tested for HIV and their clinical characteristics on entry into health care system. J Gen Intern Med 1991;6:286-9.
61. Hogan AJ, Soloman DJ, Bouknight RR, et al. Underutilization of medical care services by HIV-infected women? Some preliminary results from Michigan Medicaid Program. AIDS 1991;5:338-9.
62. Kissinger P, Clark RA, Rice J, et al. Evaluation of a program to remove barriers to public health care for women with HIV infection. South Med J 1995;88:1121-5.